Press release
Advanced Endometrial Cancer Pipeline Outlook Report 2024 (Updated)
Advanced Endometrial Cancer Pipeline
Key Takeaways from the Advanced Endometrial Cancer Pipeline Report
• DelveInsight's Advanced Endometrial Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Advanced Endometrial Cancer treatment.
• The leading companies working in the Advanced Endometrial Cancer market include Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
• Promising Advanced Endometrial Cancer pipeline therapies in the various stages of development include Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
• April 2024: Incyte Corporation- An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204).
• April 2024: M.D. Anderson Cancer Center- A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer.
• April 2024: Karyopharm Therapeutics Inc.- A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.
• April 2024:- NiKang Therapeutics Inc.- A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
• April 2024:- NETRIS Pharma- A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
• April 2024:- Merck Sharp & Dohme LLC- A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158).
• April 2024:- Neogene Therapeutics Inc.- An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation.
• April 2024: Blueprint Medicines Corporation- A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors.
Request a sample and discover the recent advances in Advanced Endometrial Cancer Treatment Drugs @ Advanced Endometrial Cancer Infection Pipeline Report- https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Advanced Endometrial Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Endometrial Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Endometrial Cancer clinical trial landscape.
Advanced Endometrial Cancer Overview
Metastatic or advanced uterine (endometrial) cancer is a type of cancer that originated in the lining of the uterus (endometrium) and has spread to distant areas of the body. In general, uterine cancer can metastasize to the bladder.
Find out more about Advanced Endometrial Cancer Treatment Landscape @ Drugs for Advanced Endometrial Cancer Treatment- https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Advanced Endometrial Cancer Emerging Drugs Profile
• Retifanlimab: Incyte Corporation
• Trastuzumab duocarmazine (SYD985): Byondis
Advanced Endometrial Cancer Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Advanced Endometrial Cancer. The Advanced Endometrial Cancer companies which have their Advanced Endometrial Cancer drug candidates in the most advanced stage, i.e. phase II include, Incyte Corporation.
Learn more about the emerging Advanced Endometrial Cancer Pipeline Therapies @ Advanced Endometrial Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Advanced Endometrial Cancer Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Endometrial Cancer- Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
• Advanced Endometrial Cancer pipeline therapies- Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
Dive deep into rich insights for new drugs for Advanced Endometrial Cancer treatment, Visit @ Advanced Endometrial Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Advanced Endometrial Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Endometrial Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Selinexor: Karyopharm Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Retifanlimab: Incyte Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Alsevalimab: Five Prime Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Advanced Endometrial Cancer Key Companies
18. Advanced Endometrial Cancer Key Products
19. Advanced Endometrial Cancer- Unmet Needs
20. Advanced Endometrial Cancer- Market Drivers and Barriers
21. Advanced Endometrial Cancer- Future Perspectives and Conclusion
22. Advanced Endometrial Cancer Analyst Views
23. Advanced Endometrial Cancer Key Companies
24. Appendix
For further information on the Advanced Endometrial Cancer pipeline therapeutics, reach out to Advanced Endometrial Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Endometrial Cancer Pipeline Outlook Report 2024 (Updated) here
News-ID: 3465712 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
